Validity and safety of endoscopic biliary stenting for biliary stricture associated with IgG4-related pancreatobiliary disease during steroid therapy

Abstract

Background Patients with IgG4-related sclerosing cholangitis and autoimmune pancreatitis frequently develop obstructive jaundice, which requires endoscopic biliary stenting (EBS) during steroid therapy to prevent bile duct infection from cholestasis and adverse steroid effects. However, it is controversial whether EBS during steroid therapy is advisable, because the procedure itself carries a risk of cholangitis and procedure-related adverse events. This study aimed to clarify the validity and safety of EBS for patients with biliary stricture associated with IgG4-related pancreatobiliary disease (IgG4-PBD) during steroid therapy.

Methods We enrolled 59 patients who presented with biliary stricture exhibiting jaundice or liver dysfunction and who were treated with EBS. The incidences of recurrent biliary obstruction and acute cholangitis were compared for EBS cases with and without steroid administration.

Results EBS was present in 55 periods with steroid administration and 110 periods without. The incidence of recurrent biliary obstruction was significantly lower in cases with steroids than in those without (1-month no obstruction rate: 100 % vs. 82 %; log-rank test P = 0.0015). The incidence of acute cholangitis related to stenting was significantly lower in cases with steroids than in those without (1-month no acute cholangitis rate: 100 % vs. 90 %; log-rank test P = 0.0278). Biliary stents could be removed without acute cholangitis, liver dysfunction, or stent replacement in 96 % of patients who underwent endoscopic retrograde cholangiopancreatography 1 month after commencing steroid administration.

Conclusions EBS during steroid administration was both valid and safe in patients with biliary stricture associated with IgG4-PBD. Stents could be safely removed 1 month after steroid initiation.

• References

• 1 Hamano H, Kawa S, Horiuchi A. et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis. NEJM 2001; 344: 732-738
• 2 Zen Y, Harada K, Sasaki M. et al. IgG4-related sclerosing cholangitis with and without hepatic inflammatory pseudotumor, and sclerosing pancreatitis-associated sclerosing cholangitis: do they belong to a spectrum of sclerosing pancreatitis?. Am J Surg Pathol 2004; 28: 1193-1203
• 3 Ghazale A, Chari ST, Zhang L. et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 2008; 134: 706-715
• 4 Hirano K, Tada M, Isayama H. et al. Long-term prognosis of autoimmune pancreatitis with and without corticosteroid treatment. Gut 2007; 56: 1719-1724
• 5 Nakazawa T, Ohara H, Sano H. et al. Clinical differences between primary sclerosing cholangitis and sclerosing cholangitis with autoimmune pancreatitis. Pancreas 2005; 30: 20-25
• 6 Ohara H, Okazaki K, Tsubouchi H. et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci 2012; 19: 536-542
• 7 Hamano H, Kawa S, Uehara T. et al. Immunoglobulin G4-related lymphoplasmacytic sclerosing cholangitis that mimics infiltrating hilar cholangiocarcinoma: part of a spectrum of autoimmune pancreatitis?. Gastrointest Endosc 2005; 62: 152-157
• 8 Lin J, Cummings OW, Greenson JK. et al. IgG4-related sclerosing cholangitis in the absence of autoimmune pancreatitis mimicking extrahepatic cholangiocarcinoma. Scand J Gastroenterol 2015; 50: 447-453
• 9 Zaydfudim VM, Wang AY, de Lange EE. et al. IgG4-associated cholangitis can mimic hilar cholangiocarcinoma. Gut Liver 2015; 9: 556-560
• 10 Kamisawa T, Takuma K, Anjiki H. et al. Sclerosing cholangitis associated with autoimmune pancreatitis differs from primary sclerosing cholangitis. World J Gastroenterol 2009; 15: 2357-2360
• 11 Nakazawa T, Ohara H, Sano H. et al. Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas 2006; 32: 229
• 12 Nakazawa T, Ohara H, Sano H. et al. Cholangiography can discriminate sclerosing cholangitis with autoimmune pancreatitis from primary sclerosing cholangitis. Gastrointest Endosc 2004; 60: 937-944
• 13 Hirano K, Tada M, Isayama H. et al. Endoscopic evaluation of factors contributing to intrapancreatic biliary stricture in autoimmune pancreatitis. Gastrointest Endosc 2010; 71: 85-90
• 14 Inui K, Yoshino J, Miyoshi H. Differential diagnosis and treatment of biliary strictures. Clin Gastroenterol Hepatol 2009; 7: S79-83
• 15 Naitoh I, Nakazawa T, Hayashi K. et al. Comparison of intraductal ultrasonography findings between primary sclerosing cholangitis and IgG4-related sclerosing cholangitis. J Gastroenterol Hepatol 2015; 30: 1104-1109
• 16 Naitoh I, Nakazawa T, Ohara H. et al. Endoscopic transpapillary intraductal ultrasonography and biopsy in the diagnosis of IgG4-related sclerosing cholangitis. J Gastroenterol 2009; 44: 1147-1155
• 17 Kawakami H, Zen Y, Kuwatani M. et al. IgG4-related sclerosing cholangitis and autoimmune pancreatitis: histological assessment of biopsies from Vater’s ampulla and the bile duct. J Gastroenterol Hepatol 2010; 25: 1648-1655
• 18 Huggett MT, Culver EL, Kumar M. et al. Type 1 autoimmune pancreatitis and IgG4-related sclerosing cholangitis is associated with extrapancreatic organ failure, malignancy, and mortality in a prospective UK cohort. Am J Gastroenterol 2014; 109: 1675-1683
• 19 Tanaka A, Tazuma S, Okazaki K. et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis. Clin Gastroenterol Hepatol 2017; 15: 920-926 e923
• 20 Hart PA, Kamisawa T, Brugge WR. et al. Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis. Gut 2013; 62: 1771-1776
• 21 Andriulli A, Loperfido S, Napolitano G. et al. Incidence rates of post–ERCP complications: a systematic survey of prospective studies. Am J Gastroenterol 2007; 102: 1781-1788
• 22 Barkay O, Khashab M, Al-Haddad M. et al. Minimizing complications in pancreaticobiliary endoscopy. Curr Gastroenterol Rep 2009; 11: 134-141
• 23 Ismail S, Kylanpaa L, Mustonen H. et al. Risk factors for complications of ERCP in primary sclerosing cholangitis. Endoscopy 2012; 44: 1133-1138
• 24 Kapral C, Muhlberger A, Wewalka F. et al. Quality assessment of endoscopic retrograde cholangiopancreatography: results of a running nationwide Austrian benchmarking project after 5 years of implementation. Eur J Gastroenterol Hepatol 2012; 24: 1447-1454
• 25 Loperfido S, Angelini G, Benedetti G. et al. Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study. Gastrointest Endosc 1998; 48: 1-10
• 26 Masci E, Toti G, Mariani A. et al. Complications of diagnostic and therapeutic ERCP: a prospective multicenter study. Am J Gastroenterol 2001; 96: 417-423
• 27 Chandrasekhara V, Khashab MA, Muthusamy VR. et al. Adverse events associated with ERCP. Gastrointest Endosc 2017; 85: 32-47
• 28 Freeman ML, Nelson DB, Sherman S. et al. Complications of endoscopic biliary sphincterotomy. NEJM 1996; 335: 909-918
• 29 Bi Y, Hart PA, Law R. et al. Obstructive jaundice in autoimmune pancreatitis can be safely treated with corticosteroids alone without biliary stenting. Pancreatology 2016; 16: 391-396
• 30 Kamisawa T, Okazaki K, Kawa S. et al. Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 III. Treatment and prognosis of autoimmune pancreatitis. J Gastroenterol 2014; 49: 961-970
• 31 Cotton PB, Lehman G, Vennes J. et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991; 37: 383-393
• 32 Isayama H, Hamada T, Yasuda I. et al. TOKYO criteria 2014 for transpapillary biliary stenting. Dig Endosc 2015; 27: 259-264
• 33 Iwasaki S, Kamisawa T, Koizumi S. et al. Assessment in steroid trial for IgG4-related sclerosing cholangitis. Adv Med Sci 2015; 60: 211-215
• 34 Naitoh I, Nakazawa T, Okumura F. et al. Endoscopic retrograde cholangiopancreatography-related adverse events in patients with type 1 autoimmune pancreatitis. Pancreatology 2016; 16: 78-82
• 35 Moon SH, Kim MH, Park DH. et al. Is a 2-week steroid trial after initial negative investigation for malignancy useful in differentiating autoimmune pancreatitis from pancreatic cancer? A prospective outcome study. Gut 2008; 57: 1704-1712